Last updated: September 7, 2026
Natalizumab remains a high-value multiple sclerosis biologic despite mature-market erosion. Biogen’s Tysabri generated approximately $1.8 billion to $2.0 billion in annual revenue in recent years, but its trajectory is under pressure from anti-CD20 therapies, oral disease-modifying treatments and the U.S. launch of the first natalizumab biosimilar, Tyruko. The commercial outlook depends on how quickly payers convert patients, whether physicians preserve natalizumab for high-efficacy or JCV-negative patients, and how much market share Tyruko captures through discounts.
Tyruko, developed by Sandoz and Polpharma Biologics, is the first FDA-approved natalizumab biosimilar. Its approval creates the first direct biologic price competitor to Tysabri in the United States. The product has the same principal indications as Tysabri, including relapsing forms of multiple sclerosis and moderately to severely active Crohn’s disease in appropriate patients.[1]
What is the current market position of natalizumab?
Natalizumab is a monoclonal antibody targeting alpha-4 integrin. It blocks leukocyte migration across the blood-brain barrier and is used primarily for highly active relapsing multiple sclerosis. It is also approved for selected patients with Crohn’s disease.
Biogen markets Tysabri globally. The product is administered intravenously every four weeks, with a subcutaneous formulation also available in several markets. Natalizumab is generally positioned as a high-efficacy therapy rather than a low-cost maintenance treatment.
| Market factor |
Current effect on natalizumab |
| Multiple sclerosis efficacy |
Supports continued use in highly active disease |
| Anti-JC virus monitoring |
Limits use in some patients because of progressive multifocal leukoencephalopathy risk |
| Anti-CD20 competition |
Reduces new-start volume and treatment-switch opportunities |
| Biosimilar entry |
Creates direct price and contracting pressure |
| Infusion-center administration |
Supports provider control but adds cost and logistical friction |
| Subcutaneous delivery |
Improves convenience and can reduce administration burden |
| Crohn’s disease contribution |
Expands the addressable market but is smaller than MS |
| Long clinical experience |
Supports physician confidence and payer coverage |
Tysabri’s strongest commercial position is in patients needing rapid, high-efficacy control of relapsing MS. Its weakest position is among treatment-naive patients for whom physicians increasingly consider ocrelizumab, ofatumumab, ublituximab or other high-efficacy agents.
How much revenue does Tysabri generate?
Biogen does not report a separate global market total for all natalizumab products. The most useful public financial proxy is Tysabri revenue reported by Biogen.
| Fiscal year |
Approximate Tysabri revenue |
Commercial interpretation |
| 2021 |
About $2.0 billion |
Mature high-value franchise |
| 2022 |
About $2.0 billion |
Stable demand before broad biosimilar impact |
| 2023 |
About $1.9 billion |
Early pressure from MS competition and pricing |
| 2024 |
Approximately $1.8 billion to $1.9 billion |
Biosimilar launch increases U.S. risk |
Figures are rounded from Biogen financial disclosures and should not be treated as a consolidated natalizumab market estimate.[2][3]
Tysabri revenue has remained resilient because the product has several commercial advantages:
- It has a long record of high efficacy in relapsing MS.
- It is used in patients with aggressive disease who may not respond adequately to lower-efficacy agents.
- Switching can create disease-control concerns, especially in patients with prior highly active disease.
- The product has established monitoring and risk-management infrastructure.
- The subcutaneous formulation gives Biogen another delivery option.
The revenue base is still structurally exposed. A mature product with annual sales near $2 billion can lose revenue through three separate channels: lower new-patient starts, switching to competing mechanisms, and net price erosion after biosimilar adoption.
When did natalizumab lose regulatory exclusivity?
Natalizumab’s U.S. biologic reference-product exclusivity expired before Tyruko’s approval. The FDA approved Tysabri in 2004, and the 12-year reference-product exclusivity period under the Biologics Price Competition and Innovation Act ended in 2016.[1]
Regulatory exclusivity and patent protection are separate. The end of biologic exclusivity permitted biosimilar applications, but commercial entry also depended on patent disputes, settlement agreements and launch strategy.
| Milestone |
Date |
| FDA approval of Tysabri |
November 2004 |
| U.S. reference-product exclusivity period |
Expired in 2016 |
| EMA authorization of Tysabri |
2006 |
| FDA approval of Tyruko |
August 2023 |
| U.S. commercial launch of Tyruko |
2024 |
Tysabri does not have small-molecule-style Orange Book exclusivity. Biological products are listed in the FDA Purple Book, which identifies reference products, biosimilars and interchangeability status.[4]
What patents protect Tysabri and natalizumab?
Natalizumab protection has historically relied on antibody composition, humanization, therapeutic-use, formulation, manufacturing and delivery-related patent claims. The practical commercial barrier is now weaker than it was during the product’s launch period because the core exclusivity window has ended and FDA-approved biosimilar competition exists.
Public patent analysis should distinguish among:
- Core anti-alpha-4 integrin antibody patents
- Humanized antibody sequence patents
- Methods of treating multiple sclerosis
- Crohn’s disease treatment claims
- Subcutaneous delivery and administration patents
- Manufacturing and cell-line patents
- Risk-management and dosing-related claims
The core Tysabri patent estate is mature. Later-filed formulation, dosing and delivery patents can still affect litigation and settlement terms, but they are less likely to preserve a broad product monopoly once a biosimilar has demonstrated analytical and clinical similarity.
A patent-by-patent freedom-to-operate conclusion requires review of the FDA Purple Book, USPTO records, Orange Book-like patent disclosures where applicable, European Patent Register data and litigation dockets. Public sources do not provide one definitive global expiration date for every natalizumab-related claim. The economically relevant issue is whether remaining claims can block or delay a biosimilar launch, not whether any patent remains nominally active.
What is the FDA regulatory status of Tyruko?
Tyruko, or natalizumab-sztn, received FDA approval in August 2023 as a biosimilar to Tysabri.[1] The approved product covers relapsing forms of multiple sclerosis and moderately to severely active Crohn’s disease in patients who have had an inadequate response to conventional therapies or who cannot tolerate them.
The product is subject to the same core clinical risk-management environment as Tysabri. Natalizumab is associated with progressive multifocal leukoencephalopathy, a rare but potentially fatal brain infection caused by JC virus reactivation. The U.S. Tysabri risk-management system requires controlled distribution, prescriber and patient enrollment, and ongoing monitoring.
The FDA’s approval of Tyruko did not automatically make the product interchangeable with Tysabri. Interchangeability is a separate FDA designation that can affect pharmacy-level substitution under state law. A biosimilar can be approved without being interchangeable.
Does Tyruko create a biosimilar substitution risk?
Yes. Tyruko creates direct substitution and contracting risk, but the pace of conversion is likely to be slower than for pharmacy-dispensed products.
Natalizumab is generally administered through controlled channels involving neurologists, infusion providers, specialty pharmacies and hospital systems. Treatment decisions are therefore influenced by:
- Physician confidence in immunogenicity and efficacy
- Patient stability on existing therapy
- Payer prior authorization rules
- Infusion-provider economics
- Product acquisition cost
- Risk-management enrollment requirements
- Availability of subcutaneous administration
- Contracting rebates and preferred formulary status
The first biosimilar often gains share through new starts and payer-mandated switching. Stable patients may remain on Tysabri when clinicians perceive switching risk or when Biogen offers competitive rebates.
How strong is the natalizumab patent estate?
The natalizumab patent estate is commercially moderate rather than strong.
Its strengths are the product’s clinical differentiation, long safety-monitoring history and complex distribution infrastructure. Its weaknesses are the end of reference-product exclusivity, the availability of an FDA-approved biosimilar and the lack of a simple patent mechanism that can permanently prevent substitution across all markets.
| Patent-estate factor |
Assessment |
| Core molecule protection |
Mature and largely exhausted as a broad commercial barrier |
| Manufacturing complexity |
Meaningful biosimilar development barrier |
| Clinical risk-management system |
Operational barrier, not conventional patent protection |
| Subcutaneous formulation |
Can support product differentiation |
| Method-of-use claims |
Potentially useful but vulnerable to validity and scope challenges |
| Biosimilar approval pathway |
Reduces the importance of blocking every patent claim |
| Global coverage |
Fragmented by jurisdiction |
Manufacturing remains a meaningful barrier. Natalizumab is a complex antibody produced through a controlled biologic process. A biosimilar sponsor must establish analytical similarity, process consistency, pharmacokinetic comparability and sufficient clinical support. That barrier protects the incumbent from rapid generic-style commoditization, but it does not prevent well-capitalized competitors from entering.
Which companies are challenging Tysabri?
The principal direct competitor is Sandoz, whose Tyruko is manufactured through the Polpharma Biologics partnership. Tyruko is the only FDA-approved natalizumab biosimilar publicly established in the U.S. market as of the latest broadly available regulatory data.
Indirect competitors include:
- Roche’s Ocrevus, or ocrelizumab
- Novartis’s Kesimpta, or ofatumumab
- TG Therapeutics’ Briumvi, or ublituximab
- Sanofi’s Aubagio legacy franchise and other MS products
- Generic dimethyl fumarate and other oral MS therapies
- Merck KGaA’s Mavenclad in selected treatment settings
- AbbVie’s Skyrizi and Takeda’s Entyvio in Crohn’s disease
Ocrevus and Kesimpta are particularly important because they compete for the same high-efficacy MS treatment population. Their mechanisms differ, but treatment guidelines and physician practice increasingly evaluate them as alternatives to natalizumab.
How does natalizumab compare with competing MS biologics?
| Product |
Mechanism |
Administration |
Main commercial advantage |
Main risk to natalizumab |
| Tysabri/Tyruko |
Alpha-4 integrin inhibition |
IV or SC natalizumab, depending on market |
Rapid, high-efficacy disease control |
PML monitoring and biosimilar pressure |
| Ocrevus |
CD20 B-cell depletion |
IV |
Strong efficacy and established use in RMS and PPMS |
New-start displacement |
| Kesimpta |
CD20 B-cell depletion |
Self-administered SC |
Home administration and convenience |
Takes patients away from infusion-based care |
| Briumvi |
CD20 B-cell depletion |
IV |
High-efficacy positioning |
Crowded high-efficacy segment |
| Oral therapies |
Multiple mechanisms |
Oral |
Convenience and broad prescriber familiarity |
Lower administration friction |
Natalizumab can retain an advantage when rapid disease suppression, pregnancy planning considerations, or prior treatment history favor its use. It is less attractive where self-administration, reduced infusion visits or long-interval dosing drive treatment selection.
What is the outlook for Crohn’s disease revenue?
Crohn’s disease is strategically important but is unlikely to offset the full MS-related pressure on Tysabri.
Natalizumab’s Crohn’s disease label is narrower than those of several competing biologics. The product is used after inadequate response or intolerance to conventional therapies. Its use is constrained by PML risk and by the availability of gut-selective and broader immunologic agents.
Key Crohn’s disease competitors include:
- Vedolizumab
- Ustekinumab
- Risankizumab
- Infliximab and biosimilars
- Adalimumab and biosimilars
- Upadacitinib
Tyruko’s Crohn’s disease approval increases the potential for payer substitution, but the indication’s narrower role reduces its ability to drive the overall natalizumab market.
What patent litigation and settlement issues affect natalizumab?
The central legal issue is biosimilar entry rather than a new composition-of-matter dispute. Biosimilar sponsors typically face patent dance disclosures, infringement claims and possible settlement negotiations under the BPCIA framework.
The commercial outcomes usually fall into three categories:
- Immediate launch after regulatory approval and patent resolution.
- A negotiated launch date before all asserted patents expire.
- Delayed launch caused by injunction risk or settlement restrictions.
Tyruko’s 2024 U.S. launch indicates that patent barriers did not prevent commercial entry. The remaining disputes, if any, are more likely to affect launch timing, market access and pricing than the existence of biosimilar competition itself.
No broad assumption should be made that every remaining natalizumab patent is enforceable against every biosimilar manufacturing process. Patent strength depends on claim scope, validity, infringement evidence and jurisdiction.
What generic and biosimilar launch scenarios exist?
Base case: gradual erosion
Tysabri retains most incumbent patients, while Tyruko captures new starts and a portion of payer-directed switches. Net price declines are moderate, and global Tysabri revenue falls gradually.
Downside case: accelerated payer conversion
Large U.S. payers designate Tyruko as preferred, infusion providers accept lower acquisition costs and neurologists switch stable patients. Tysabri revenue declines faster through both volume and rebate pressure.
Defensive case: franchise segmentation
Biogen protects higher-risk or highly stable patients, expands subcutaneous use, uses contracting to preserve access and emphasizes clinical familiarity. Tyruko gains share primarily among new patients and price-sensitive accounts.
A reasonable commercial planning range is a 15% to 30% cumulative erosion in Tysabri revenue over the first several years of effective biosimilar competition under a moderate scenario. Faster erosion is possible if multiple natalizumab biosimilars enter or if payers impose mandatory substitution. Slower erosion is possible because administration is physician-controlled and the safety-monitoring system is complex.
These percentages are scenario assumptions, not reported market forecasts.
What is the likely financial trajectory for natalizumab?
The most likely trajectory is declining but still material revenue through the late 2020s.
| Period |
Expected market condition |
Financial effect |
| 2024-2025 |
First U.S. biosimilar commercialization |
Initial price and new-start pressure |
| 2025-2026 |
Payer and provider contracting develops |
Greater share transfer to Tyruko and potential entrants |
| 2026-2028 |
Biosimilar adoption broadens |
Revenue erosion becomes more volume-driven |
| Late 2020s |
Mature multi-product market |
Natalizumab becomes a lower-price, segmented high-efficacy franchise |
Tysabri is unlikely to experience the abrupt collapse associated with a small-molecule generic cliff. The product has complex administration, risk controls, specialist prescribing and substantial switching friction. The more probable outcome is a multi-year decline with margin pressure preceding a sharp loss of patient volume.
Biogen’s exposure is concentrated because Tysabri is a major product within its MS portfolio. Revenue risk is amplified by competition affecting other legacy MS products, including Tecfidera and Vumerity, while newer assets and pipeline products must offset the erosion.
How does natalizumab compare with other biologic patent cliffs?
Natalizumab’s competitive transition is less severe than a pure small-molecule patent cliff but more exposed than a biologic with no approved biosimilar.
| Product type |
Typical erosion pattern |
| Small-molecule brand after generic entry |
Rapid price and volume loss |
| Biologic after one biosimilar |
Gradual, payer-dependent erosion |
| Biologic after multiple biosimilars |
More rapid price compression |
| Natalizumab |
Gradual erosion with strong specialist and safety-monitoring friction |
The primary investment question is not whether natalizumab will retain clinical value. It is whether clinical value will translate into premium net pricing after payers can choose an FDA-approved biosimilar.
Key Takeaways
- Tysabri remains a roughly $1.8 billion to $2.0 billion global franchise based on Biogen-reported revenue.
- The U.S. reference-product exclusivity period ended in 2016.
- Tyruko, approved by the FDA in August 2023, is the first major direct biosimilar threat.
- Natalizumab faces stronger clinical competition from Ocrevus, Kesimpta and Briumvi than from biosimilars alone.
- The patent estate is mature; manufacturing complexity and clinical risk controls are more important commercial barriers.
- Tysabri revenue is likely to decline gradually rather than collapse immediately.
- Crohn’s disease is a secondary revenue contributor and is unlikely to fully offset MS erosion.
- The principal financial risks are payer-driven switching, lower net price and broader adoption of anti-CD20 therapies.
FAQs
Is natalizumab still commercially attractive after biosimilar entry?
Yes. Natalizumab remains attractive in highly active relapsing MS because of its efficacy, established monitoring system and physician familiarity. Its commercial value is lower than before biosimilar competition because premium pricing is under pressure.
Is Tyruko interchangeable with Tysabri?
FDA biosimilar approval and FDA interchangeability are separate determinations. Tyruko’s biosimilar approval does not by itself establish pharmacy-level interchangeable substitution in every state.
What is the biggest clinical risk affecting natalizumab sales?
Progressive multifocal leukoencephalopathy risk associated with JC virus is the principal product-specific concern. Required monitoring can also make treatment more complex than some competing therapies.
Will natalizumab biosimilars receive the same Crohn’s disease market access as Tysabri?
Not automatically. Payers may prefer a biosimilar, but Crohn’s disease use is narrower and treatment selection depends on prior therapy, disease location, safety factors and competing biologic contracts.
Can subcutaneous natalizumab protect Biogen from biosimilar competition?
It can reduce switching by offering convenience and a differentiated administration option, but it does not eliminate biosimilar risk. The strength of the defense depends on payer coverage, physician preference and whether competing biosimilars offer comparable delivery options.
References
- U.S. Food and Drug Administration. (2023). FDA approves first biosimilar to Tysabri to treat multiple sclerosis and Crohn’s disease. https://www.fda.gov
- Biogen Inc. (2023). 2023 annual report. https://investors.biogen.com
- Biogen Inc. (2024). 2024 annual report. https://investors.biogen.com
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- European Medicines Agency. (2023). Tyruko: EPAR. https://www.ema.europa.eu
